Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Hundreds of lawsuits allege that insulin manufacturers and pharmacy benefit managers colluded to raise prices. The ...

Jefferies analyst Benjamin Jackson CFA maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Global pharma giants establish GCCs in India for digital transformation, leveraging tech talent, political stability, and ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Sanofi: Which Is the Better Investment Right ... play a decisive role in determining which of Novo Nordisk and Eli Lilly has the greater investment attractiveness in the "Current Valuation ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

European pharma companies warned the European Commission president at a meeting on Tuesday that U.S. tariffs would expedite ...